APN normalised EPS from continuing ops rises 28% on improved outlook
APN said normalised headline EPS from continuing operations grew 28% at constant exchange rates, backed by stronger Commercial Pharmaceuticals and Manufacturing EBITDA. It also cited an APAC divestment unlocking R28 billion to support buybacks and higher dividends.
Normalised headline EPS from continuing operations grew 28% at constant exchange rates, driven by strong Commercial Pharmaceuticals and Manufacturing EBITDA growth.
The APAC divestment unlocked R28 billion, strengthening the balance sheet and enabling share buybacks and higher dividends.Original do…